For the year ending 2025-12-31, AGEN has $226,798K in assets. $2,998K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 2,998 | |||
| Accounts receivable | 1,831 | |||
| Related party note receivable from mink therapeutics, inc | 5,179 | |||
| Prepaid expenses | 785 | |||
| Assets held for sale | 121,554 | |||
| Other current assets | 1,089 | |||
| Total current assets | 133,436 | |||
| Property, plant and equipment, gross | 62,938 | |||
| Plant and equipment, accumulated amortization and depreciation | 47,468 | |||
| Property, plant and equipment, net of accumulated amortization and depreciation of 47,468 and 72,553 at december 31, 2025 and 2024, respectively | 15,470 | |||
| Operating lease right-of-use assets | 7,744 | |||
| Goodwill | 24,092 | |||
| Acquired intangible assets, net of accumulated amortization of 17,325 and 16,986 at december 31, 2025 and 2024, respectively | 3,037 | |||
| Equity method investment in mink therapeutics, inc | 24,277 | |||
| Due from related parties (mink therapeutics, inc.) | 15,435 | |||
| Other long-term assets | 3,307 | |||
| Total assets | 226,798 | |||
| Current portion, long-term debt | 44,655 | |||
| Current portion, liability related to sale of future royalties and milestones | 109,323 | |||
| Current portion, deferred revenue | 0 | |||
| Current portion, operating lease liabilities | 1,034 | |||
| Accounts payable | 82,987 | |||
| Accrued liabilities | 34,223 | |||
| Liabilities held for sale | 50,738 | |||
| Other current liabilities | 529 | |||
| Total current liabilities | 323,489 | |||
| Long-term debt, net of current portion | 0 | |||
| Liability related to sale of future royalties and milestones, net of current portion | 169,660 | |||
| Deferred revenue, net of current portion | 1,143 | |||
| Operating lease liabilities, net of current portion | 10,108 | |||
| Other long-term liabilities | 259 | |||
| Series a-1 convertible preferred stock 31,620 shares designated, issued, and outstanding at december 31, 2025 and 2024 liquidation value of 34,317 and 34,101 at december 31, 2025, and 2024, respectively | 0 | |||
| Common stock, par value 0.01 per share 800,000,000 shares authorized at december 31, 2025 and 2024 35,320,397 shares and 23,634,670 shares issued and outstanding at december 31, 2025 and 2024, respectively | 353 | |||
| Additional paid-in capital | 1,911,740 | |||
| Accumulated other comprehensive loss | -439 | |||
| Accumulated deficit | -2,182,765 | |||
| Total stockholders' deficit attributable to agenus inc | -271,111 | |||
| Non-controlling interest | -6,750 | |||
| Total stockholders' deficit | -277,861 | |||
| Total liabilities, convertible preferred stock and stockholders' deficit | 226,798 | |||
AGENUS INC (AGEN)
AGENUS INC (AGEN)